Accès ouvert

Saliva is superior over nasopharyngeal swab for detecting SARS-CoV2 in COVID-19 patients

Article scientifique 2021 Anglais

Résumé

Scaling up of diagnostic capacity is needed to mitigate the global pandemic of SARS-CoV2. However, there are challenges including shortage of sample collection swabs and transport medium. Saliva has been recommended as a simple, low-cost, non-invasive option. However, data from different populations and settings are limited. Here, we showed that saliva could be a good alternative sample to diagnose COVID-19 patients. Pair of NPS-saliva samples was collected from 152 symptomatic; confirmed COVID-19 patients, and compared their positivity rate, viral load, and duration of viral shedding. From 152 patients, 80 (52.63%) tested positive and 72 (47.37%) were negative for SARSA-CoV2 in NPS sample. In saliva, 129 (92.14%) were tested positive and 11 (7.86%) were negative on the day of admission to hospital. The overall percent agreement of RT-PCR result of Saliva to NPS was 70% (196/280). A comparison of viral load from 72 NPS-saliva pair samples on day of admission shows saliva contains significantly higher viral load (P < 0.001). In conclusion, saliva has higher yield in detecting SARS-CoV2, and COVID-19 patients show higher viral load and prolonged period of viral shedding in saliva. Therefore, we recommend saliva as a better alternative sample to NPS to diagnose COVID-19 patients.

Citer ce document

Beyene, G., Alemu, F., Kebede, E., Alemayehu, D., Seyoum, T., Tefera, D., Assefa, G., Tesfaye, A., Habte, A., Bedada, G., Tegene, B., Yeshambaw, M., Wassie, L., Mihret, A., Abdissa, A., Mulu, A. (2021). Saliva is superior over nasopharyngeal swab for detecting SARS-CoV2 in COVID-19 patients. https://doi.org/10.1038/s41598-021-02097-2

Accès au document

Voir sur le dépôt source

Ce document est hébergé sur son dépôt institutionnel d'origine.

Statistiques

Consultations : 1

Téléchargements : 0